144 related articles for article (PubMed ID: 10530940)
21. P450-dependent enzymes as targets for prostate cancer therapy.
De Coster R; Wouters W; Bruynseels J
J Steroid Biochem Mol Biol; 1996 Jan; 56(1-6 Spec No):133-43. PubMed ID: 8603034
[TBL] [Abstract][Full Text] [Related]
22. The role of fluorine substitution in biphenyl methylene imidazole-type CYP17 inhibitors for the treatment of prostate carcinoma.
Hu Q; Negri M; Olgen S; Hartmann RW
ChemMedChem; 2010 Jun; 5(6):899-910. PubMed ID: 20437447
[TBL] [Abstract][Full Text] [Related]
23. Novel nonsteroidal inhibitor of cytochrome P450(17alpha) (17alpha-hydroxylase/C17-20 lyase), YM116, decreased prostatic weights by reducing serum concentrations of testosterone and adrenal androgens in rats.
Ideyama Y; Kudoh M; Tanimoto K; Susaki Y; Nanya T; Nakahara T; Ishikawa H; Yoden T; Okada M; Fujikura T; Akaza H; Shikama H
Prostate; 1998 Sep; 37(1):10-8. PubMed ID: 9721064
[TBL] [Abstract][Full Text] [Related]
24. Synthesis and biological evaluation of imidazole based compounds as cytochrome P-450 inhibitors.
Ahmed S; Smith JH; Nicholls PJ; Whomsley R; Cariuk P
Drug Des Discov; 1995 Aug; 13(1):27-41. PubMed ID: 8882899
[TBL] [Abstract][Full Text] [Related]
25. Synthesis and biochemical evaluation of a range of (4-substituted phenyl)sulfonate derivatives of 4-hydroxybenzyl imidazole-based compounds as potent inhibitors of 17alpha-hydroxylase/17,20-lyase (P45017alpha) derived from rat testicular microsomes.
Owen CP; Shahid I; Lee WY; Ahmed S
Bioorg Med Chem Lett; 2010 Sep; 20(17):5345-8. PubMed ID: 20675132
[TBL] [Abstract][Full Text] [Related]
26. Novel P450(17alpha) inhibitors: 17-(2'-oxazolyl)- and 17-(2'-thiazolyl)-androstene derivatives.
Zhu N; Ling Y; Lei X; Handratta V; Brodie AM
Steroids; 2003 Sep; 68(7-8):603-11. PubMed ID: 12957665
[TBL] [Abstract][Full Text] [Related]
27. Esters of 3-pyridylacetic acid that combine potent inhibition of 17 alpha-hydroxylase/C17,20-lyase (cytochrome P45017 alpha) with resistance to esterase hydrolysis.
Rowlands MG; Barrie SE; Chan F; Houghton J; Jarman M; McCague R; Potter GA
J Med Chem; 1995 Oct; 38(21):4191-7. PubMed ID: 7473546
[TBL] [Abstract][Full Text] [Related]
28. 6-Substituted 3,4-dihydro-naphthalene-2-carboxylic acids: synthesis and structure-activity studies in a novel class of human 5alpha reductase inhibitors.
Baston E; Salem OI; Hartmann RW
J Enzyme Inhib Med Chem; 2002 Oct; 17(5):303-20. PubMed ID: 12683747
[TBL] [Abstract][Full Text] [Related]
29. Antiandrogenic effects of novel androgen synthesis inhibitors on hormone-dependent prostate cancer.
Long BJ; Grigoryev DN; Nnane IP; Liu Y; Ling YZ; Brodie AM
Cancer Res; 2000 Dec; 60(23):6630-40. PubMed ID: 11118046
[TBL] [Abstract][Full Text] [Related]
30. Pyridyl substituted benzocycloalkenes: new inhibitors of 17 alpha-hydroxylase/17,20-lyase (P450 17 alpha).
Sergejew T; Hartmann RW
J Enzyme Inhib; 1994; 8(2):113-22. PubMed ID: 7539071
[TBL] [Abstract][Full Text] [Related]
31. A new class of nonsteroidal aromatase inhibitors: design and synthesis of chromone and xanthone derivatives and inhibition of the P450 enzymes aromatase and 17 alpha-hydroxylase/C17,20-lyase.
Recanatini M; Bisi A; Cavalli A; Belluti F; Gobbi S; Rampa A; Valenti P; Palzer M; Palusczak A; Hartmann RW
J Med Chem; 2001 Mar; 44(5):672-80. PubMed ID: 11262078
[TBL] [Abstract][Full Text] [Related]
32. Isopropylidene substitution increases activity and selectivity of biphenylmethylene 4-pyridine type CYP17 inhibitors.
Hu Q; Yin L; Jagusch C; Hille UE; Hartmann RW
J Med Chem; 2010 Jul; 53(13):5049-53. PubMed ID: 20550118
[TBL] [Abstract][Full Text] [Related]
33. Growth inhibition of human prostate cells in vitro by novel inhibitors of androgen synthesis.
Klus GT; Nakamura J; Li JS; Ling YZ; Son C; Kemppainen JA; Wilson EM; Brodie AM
Cancer Res; 1996 Nov; 56(21):4956-64. PubMed ID: 8895750
[TBL] [Abstract][Full Text] [Related]
34. Effects of new 17alpha-hydroxylase/C(17,20)-lyase inhibitors on LNCaP prostate cancer cell growth in vitro and in vivo.
Grigoryev DN; Long BJ; Nnane IP; Njar VC; Liu Y; Brodie AM
Br J Cancer; 1999 Oct; 81(4):622-30. PubMed ID: 10574247
[TBL] [Abstract][Full Text] [Related]
35. 20-amino and 20,21-aziridinyl pregnene steroids: development of potent inhibitors of 17 alpha-hydroxylase/C17,20-lyase (P450 17).
Njar VC; Hector M; Hartmann RW
Bioorg Med Chem; 1996 Sep; 4(9):1447-53. PubMed ID: 8894102
[TBL] [Abstract][Full Text] [Related]
36. 3- and 4-pyridylalkyl adamantanecarboxylates: inhibitors of human cytochrome P450(17 alpha) (17 alpha-hydroxylase/C17,20-lyase). Potential nonsteroidal agents for the treatment of prostatic cancer.
Chan FC; Potter GA; Barrie SE; Haynes BP; Rowlands MG; Houghton J; Jarman M
J Med Chem; 1996 Aug; 39(17):3319-23. PubMed ID: 8765515
[TBL] [Abstract][Full Text] [Related]
37. 1-imidazolyl(alkyl)-substituted di- and tetrahydroquinolines and analogues: syntheses and evaluation of dual inhibitors of thromboxane A(2) synthase and aromatase.
Jacobs C; Frotscher M; Dannhardt G; Hartmann RW
J Med Chem; 2000 May; 43(9):1841-51. PubMed ID: 10794700
[TBL] [Abstract][Full Text] [Related]
38. Inhibition of aromatase (P450Arom) by some 1-(benzofuran-2-ylmethyl)imidazoles.
Owen CP; Nicholls PJ; Smith HJ; Whomsley R
J Pharm Pharmacol; 1999 Apr; 51(4):427-33. PubMed ID: 10385215
[TBL] [Abstract][Full Text] [Related]
39. Novel C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens: synthesis, in vitro biological activity, pharmacokinetics, and antitumor activity in the LAPC4 human prostate cancer xenograft model.
Handratta VD; Vasaitis TS; Njar VC; Gediya LK; Kataria R; Chopra P; Newman D; Farquhar R; Guo Z; Qiu Y; Brodie AM
J Med Chem; 2005 Apr; 48(8):2972-84. PubMed ID: 15828836
[TBL] [Abstract][Full Text] [Related]
40. Effects of novel 17-azolyl compounds on androgen synthesis in vitro and in vivo.
Nnane IP; Njar VC; Liu Y; Lu Q; Brodie AM
J Steroid Biochem Mol Biol; 1999 Dec; 71(3-4):145-52. PubMed ID: 10659703
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
